河化股份(000953) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was ¥93,283,962.41, a decrease of 50.91% compared to ¥190,023,890.74 in the same period last year[20]. - The net profit attributable to shareholders was ¥2,856,763.21, down 93.73% from ¥45,572,911.22 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥1,751,745.52, a decline of 96.15% compared to ¥45,441,914.64 in the previous year[20]. - The net cash flow from operating activities was ¥7,375,714.21, representing an 83.71% decrease from ¥45,285,557.86 in the same period last year[20]. - Basic earnings per share were ¥0.0078, down 93.95% from ¥0.1290 in the previous year[20]. - The company's revenue for the reporting period was ¥93.28 million, a decrease of 50.91% compared to ¥190.02 million in the same period last year[36]. - The net profit for the reporting period was ¥334.96 million, down 93.18% from the previous year[36]. - The gross profit margin for the pharmaceutical intermediates segment was 44.64%, down 17.19% year-on-year, while the gross profit margin for the fertilizer business was 1.43%, down 0.20% year-on-year[40]. - The net cash flow from operating activities decreased by 83.71% to ¥7,375,714.21, primarily due to a reduction in sales revenue[40]. - The company's total operating revenue for the reporting period was ¥93,283,962.41, a decrease of 50.91% compared to ¥190,023,890.74 in the same period last year[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥382,243,744.99, an increase of 1.58% from ¥376,292,912.19 at the end of the previous year[20]. - The net assets attributable to shareholders at the end of the reporting period were ¥169,847,014.84, up 1.71% from ¥166,990,251.63 at the end of the previous year[20]. - The company's total assets included cash and cash equivalents of ¥80,607,138.98, representing 21.09% of total assets, primarily due to the redemption of bank wealth management products[45]. - The company's total liabilities increased to CNY 196,468,125.83 from CNY 193,866,917.27, reflecting a growth of about 0.8%[122]. - The company's non-current assets decreased to CNY 245,166,701.57 from CNY 248,794,081.79, showing a decline of approximately 1.1%[121]. - The company's total liabilities at the end of the period were CNY 701,900,568.72, indicating a high leverage ratio[144]. Research and Development - The company continues to conduct small-scale research and pilot projects, including ongoing optimization of the T53 (Nebivolol Epoxide) process to reduce raw material costs[36]. - The company has developed new processes for T55 (Valproic Acid) and T57 (N-desmethylclobazam), with T57 samples already sent to customers for validation[36]. - The company emphasizes R&D and has a dedicated project management system to improve efficiency and reduce costs[30]. - Research and development expenses amounted to ¥3,850,668.12, a decrease of 18.18% from ¥4,706,454.31 in the previous year[40]. - The company's research and development expenses for the first half of 2021 were CNY 3,850,668.12, a decrease of 18.19% from CNY 4,706,454.31 in the first half of 2020[128]. Market and Sales - Domestic sales accounted for 73.53% of total revenue, amounting to ¥68,588,445.33, while overseas sales accounted for 26.47%, totaling ¥24,695,517.08, reflecting decreases of 47.04% and 59.20% respectively[39]. - The company has a high market share and quality-leading products, with self-operated import and export rights[32]. - The company has a flexible production model that allows for customization based on client needs, particularly for Vitamin D3 intermediates[31]. - The company has maintained a stable relationship with major clients, which is crucial for its revenue stability[58]. Environmental and Regulatory Compliance - The company emphasizes environmental protection and has taken measures to control pollution during production processes[55]. - The company has completed the construction of pollution control facilities, including a waste gas collection and treatment system with a design capacity of 30,000 m³/h and a wastewater treatment plant with a design capacity of 500 t/d[69]. - The total discharge of chemical oxygen demand (COD) is 1.55 t/a, which is below the approved discharge limit of 2.57 t/a, indicating no exceedance[69]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[73]. - The company has submitted a self-monitoring plan for environmental protection, which includes monitoring of wastewater, waste gas, and noise pollution[72]. Corporate Governance - The company has not made any changes to its board of directors or senior management during the reporting period[64]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[81]. - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[77]. - The semi-annual financial report has not been audited[79]. Financial Management - The company has a receivable from related parties amounting to 10,683.57 million CNY, with an interest rate of 4.35%[87]. - The company has a payable to related parties totaling 2,282.93 million CNY, also at an interest rate of 4.35%[87]. - The company utilized related party borrowings primarily for short-term cash flow management, ensuring operational stability without impacting financial results[87]. - The company has invested 7,650 million CNY in bank wealth management products, with an outstanding balance of 704.6 million CNY[95]. - The company reported a total share count of 366,122,195, with 25,862,068 shares released from lock-up on March 26, 2021[101]. Future Outlook - The company plans to strengthen its market expansion and product development strategies to mitigate risks associated with high customer concentration[58]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[144].